Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The approval granted last week is supported by the first phase of the Phase 3 ESSENCE trial where 37 per cent of patients on a 2.4 mg demonstrated improvement in liver fibrosis (scarring) without worsening steatohepatitis (fat buildup) after 72 weeks of treatment, compared to 22.5 per cent on placebo
Retailers are already responding to this demand
This distinction is important for ensuring patients receive the correct formulation for their primary diagnosis
It's the wrong molecule
For patients wondering about tirzepatide oral vs injectable options, the injectable version assures proven effectiveness
US$ 22.78
US$ 25.18
US$ 29.00
US$ 22.61
